Cargando…

Regulatory T Cells as Predictors of Clinical Course in Hospitalised COVID-19 Patients

BACKGROUND: The host immune response has a prominent role in the progression and outcome of SARS-CoV-2 infection. Lymphopenia has been described as an important feature of SARS-CoV-2 infection and has been associated with severe disease manifestation. Lymphocyte dysregulation and hyper-inflammation...

Descripción completa

Detalles Bibliográficos
Autores principales: Caldrer, Sara, Mazzi, Cristina, Bernardi, Milena, Prato, Marco, Ronzoni, Niccolò, Rodari, Paola, Angheben, Andrea, Piubelli, Chiara, Tiberti, Natalia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8674838/
https://www.ncbi.nlm.nih.gov/pubmed/34925369
http://dx.doi.org/10.3389/fimmu.2021.789735
_version_ 1784615757962805248
author Caldrer, Sara
Mazzi, Cristina
Bernardi, Milena
Prato, Marco
Ronzoni, Niccolò
Rodari, Paola
Angheben, Andrea
Piubelli, Chiara
Tiberti, Natalia
author_facet Caldrer, Sara
Mazzi, Cristina
Bernardi, Milena
Prato, Marco
Ronzoni, Niccolò
Rodari, Paola
Angheben, Andrea
Piubelli, Chiara
Tiberti, Natalia
author_sort Caldrer, Sara
collection PubMed
description BACKGROUND: The host immune response has a prominent role in the progression and outcome of SARS-CoV-2 infection. Lymphopenia has been described as an important feature of SARS-CoV-2 infection and has been associated with severe disease manifestation. Lymphocyte dysregulation and hyper-inflammation have been shown to be associated with a more severe clinical course; however, a T cell subpopulation whose dysfunction correlate with disease progression has yet to be identify. METHODS: We performed an immuno-phenotypic analysis of T cell sub-populations in peripheral blood from patients affected by different severity of COVID-19 (n=60) and undergoing a different clinical evolution. Clinical severity was established based on a modified WHO score considering both ventilation support and respiratory capacity (PaO2/FiO2 ratio). The ability of circulating cells at baseline to predict the probability of clinical aggravation was explored through multivariate regression analyses. RESULTS: The immuno-phenotypic analysis performed by multi-colour flow cytometry confirmed that patients suffering from severe COVID-19 harboured significantly reduced circulating T cell subsets, especially for CD4(+) T, Th1, and regulatory T cells. Peripheral T cells also correlated with parameters associated with disease severity, i.e., PaO2/FiO2 ratio and inflammation markers. CD4(+) T cell subsets showed an important significant association with clinical evolution, with patients presenting markedly decreased regulatory T cells at baseline having a significantly higher risk of aggravation. Importantly, the combination of gender and regulatory T cells allowed distinguishing between improved and worsened patients with an area under the ROC curve (AUC) of 82%. CONCLUSIONS: The present study demonstrates the association between CD4(+) T cell dysregulation and COVID-19 severity and progression. Our results support the importance of analysing baseline regulatory T cell levels, since they were revealed able to predict the clinical worsening during hospitalization. Regulatory T cells assessment soon after hospital admission could thus allow a better clinical stratification and patient management.
format Online
Article
Text
id pubmed-8674838
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-86748382021-12-17 Regulatory T Cells as Predictors of Clinical Course in Hospitalised COVID-19 Patients Caldrer, Sara Mazzi, Cristina Bernardi, Milena Prato, Marco Ronzoni, Niccolò Rodari, Paola Angheben, Andrea Piubelli, Chiara Tiberti, Natalia Front Immunol Immunology BACKGROUND: The host immune response has a prominent role in the progression and outcome of SARS-CoV-2 infection. Lymphopenia has been described as an important feature of SARS-CoV-2 infection and has been associated with severe disease manifestation. Lymphocyte dysregulation and hyper-inflammation have been shown to be associated with a more severe clinical course; however, a T cell subpopulation whose dysfunction correlate with disease progression has yet to be identify. METHODS: We performed an immuno-phenotypic analysis of T cell sub-populations in peripheral blood from patients affected by different severity of COVID-19 (n=60) and undergoing a different clinical evolution. Clinical severity was established based on a modified WHO score considering both ventilation support and respiratory capacity (PaO2/FiO2 ratio). The ability of circulating cells at baseline to predict the probability of clinical aggravation was explored through multivariate regression analyses. RESULTS: The immuno-phenotypic analysis performed by multi-colour flow cytometry confirmed that patients suffering from severe COVID-19 harboured significantly reduced circulating T cell subsets, especially for CD4(+) T, Th1, and regulatory T cells. Peripheral T cells also correlated with parameters associated with disease severity, i.e., PaO2/FiO2 ratio and inflammation markers. CD4(+) T cell subsets showed an important significant association with clinical evolution, with patients presenting markedly decreased regulatory T cells at baseline having a significantly higher risk of aggravation. Importantly, the combination of gender and regulatory T cells allowed distinguishing between improved and worsened patients with an area under the ROC curve (AUC) of 82%. CONCLUSIONS: The present study demonstrates the association between CD4(+) T cell dysregulation and COVID-19 severity and progression. Our results support the importance of analysing baseline regulatory T cell levels, since they were revealed able to predict the clinical worsening during hospitalization. Regulatory T cells assessment soon after hospital admission could thus allow a better clinical stratification and patient management. Frontiers Media S.A. 2021-12-02 /pmc/articles/PMC8674838/ /pubmed/34925369 http://dx.doi.org/10.3389/fimmu.2021.789735 Text en Copyright © 2021 Caldrer, Mazzi, Bernardi, Prato, Ronzoni, Rodari, Angheben, Piubelli and Tiberti https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Caldrer, Sara
Mazzi, Cristina
Bernardi, Milena
Prato, Marco
Ronzoni, Niccolò
Rodari, Paola
Angheben, Andrea
Piubelli, Chiara
Tiberti, Natalia
Regulatory T Cells as Predictors of Clinical Course in Hospitalised COVID-19 Patients
title Regulatory T Cells as Predictors of Clinical Course in Hospitalised COVID-19 Patients
title_full Regulatory T Cells as Predictors of Clinical Course in Hospitalised COVID-19 Patients
title_fullStr Regulatory T Cells as Predictors of Clinical Course in Hospitalised COVID-19 Patients
title_full_unstemmed Regulatory T Cells as Predictors of Clinical Course in Hospitalised COVID-19 Patients
title_short Regulatory T Cells as Predictors of Clinical Course in Hospitalised COVID-19 Patients
title_sort regulatory t cells as predictors of clinical course in hospitalised covid-19 patients
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8674838/
https://www.ncbi.nlm.nih.gov/pubmed/34925369
http://dx.doi.org/10.3389/fimmu.2021.789735
work_keys_str_mv AT caldrersara regulatorytcellsaspredictorsofclinicalcourseinhospitalisedcovid19patients
AT mazzicristina regulatorytcellsaspredictorsofclinicalcourseinhospitalisedcovid19patients
AT bernardimilena regulatorytcellsaspredictorsofclinicalcourseinhospitalisedcovid19patients
AT pratomarco regulatorytcellsaspredictorsofclinicalcourseinhospitalisedcovid19patients
AT ronzoniniccolo regulatorytcellsaspredictorsofclinicalcourseinhospitalisedcovid19patients
AT rodaripaola regulatorytcellsaspredictorsofclinicalcourseinhospitalisedcovid19patients
AT anghebenandrea regulatorytcellsaspredictorsofclinicalcourseinhospitalisedcovid19patients
AT piubellichiara regulatorytcellsaspredictorsofclinicalcourseinhospitalisedcovid19patients
AT tibertinatalia regulatorytcellsaspredictorsofclinicalcourseinhospitalisedcovid19patients